Preclinical Development of Combination Simvastatin and Metformin Chemotherapy for Metastatic Castration-Resistant Prostate Cancer

Preclinical Development of Combination Simvastatin and Metformin Chemotherapy for Metastatic Castration-Resistant Prostate Cancer

Bibliographic Details
Main Author:	Babcook, Melissa A.
Language:	English
Published:	Case Western Reserve University School of Graduate Studies / OhioLINK 2015
Subjects:	Biomedical Research Pharmaceuticals castration-resistant prostate cancer simvastatin metformin
Online Access:	http://rave.ohiolink.edu/etdc/view?acc_num=case1410439667

Similar Items

Comparison of effect of simvastatin and metformin monotherapy on lipid profile and testosterone levels in polycystic ovary syndrome
by: Veena Singh
Published: (2012-01-01)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
by: Dhruv Bansal, et al.
Published: (2021-01-01)

Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer
by: Kai-Fu Yang, et al.
Published: (2015-12-01)

Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity?
by: C. Bulcão, et al.
Published: (2007-02-01)

Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity?
by: C. Bulcão, et al.

Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer
by: Darren M.C. Poon, et al.
Published: (2015-06-01)

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
by: Caffo O, et al.
Published: (2016-12-01)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
by: Lixin Mai, et al.
Published: (2020-12-01)

Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
by: Pascoe Abigail C, et al.
Published: (2012-03-01)

Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01)

Comparison of effect of simvastatin and metformin monotherapy on lipid profile and testosterone levels in polycystic ovary syndrome
by: Veena Singh, et al.
Published: (2012-06-01)

Drug treatment opportunities of the elderly patients with the metastatic castration-resistant prostate cancer
by: V. A. Solodkiy, et al.
Published: (2017-04-01)

Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
by: Sanjoy Kumar Sureka, et al.
Published: (2016-01-01)

Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice
by: Geehyun Song, et al.
Published: (2013-09-01)

Prospects of 2nd line chemotherapy personalization in patients with metastatic castration-resistant prostate cancer
by: B. Ya. Alekseev, et al.
Published: (2016-12-01)

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience
by: Yang Liu, et al.
Published: (2021-01-01)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
by: Magdalena Schrank, et al.
Published: (2020-01-01)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
by: Monica Vidal, et al.

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
by: Patel SA, et al.
Published: (2017-08-01)

Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy
by: Minyong Kang, et al.
Published: (2015-12-01)

Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies
by: Mike Wenzel, et al.
Published: (2021-04-01)

Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
by: Donald Colbourn
Published: (2012-06-01)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
by: Chong JT, et al.
Published: (2018-04-01)

Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome
by: Ferdous Mehrabian, et al.
Published: (2016-01-01)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
by: Atsushi Mizokami, et al.
Published: (2017-01-01)

Physician preferences for non-metastatic castration-resistant prostate cancer treatment
by: Sandy Srinivas, et al.
Published: (2020-06-01)

Experimental study of apoptosis in the prostate tissue following castration
by: Y Doustar, et al.
Published: (2008-02-01)

Simvastatin enhances irinotecan-induced apoptosis in prostate cancer via inhibition of MCL-1
by: Mohammad A.Y. Alqudah, et al.
Published: (2018-02-01)

Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
by: Kim N. Chi, et al.
Published: (2013-04-01)

Radium-223 in metastatic castration resistant prostate cancer
by: Winston Vuong, et al.
Published: (2014-06-01)

NEW TREATMENT STANDARD FOR PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
by: B. Ya. Alekseev
Published: (2018-10-01)

Critical questions in metastatic castration-resistant prostate cancer: Integrating emerging clinical evidence and guideline recommendations
by: Mohamed Ali, et al.
Published: (2016-01-01)

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer
by: Tai-Lung Cha, et al.
Published: (2017-11-01)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
by: Luca Cindolo, et al.
Published: (2017-11-01)

Weekly low-dose docetaxel is an effective treatment with fewer adverse events for metastatic castration-resistant prostate cancer in Taiwanese patients
by: Cheng-Li Kao, et al.
Published: (2015-12-01)

Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
by: Luc Cabel, et al.
Published: (2017-04-01)

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients
by: DUAN Liqun, et al.
Published: (2019-09-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

Predictive factors for progression to metastatic castration-resistant prostate cancer
by: TAN Xintao, et al.
Published: (2021-03-01)

A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
by: Sang Eun Yoon, et al.
Published: (2019-05-01)

Cannot write session to /tmp/vufind_sessions/sess_3kssekmjf32rr9uvdqd9j878h8